osimertinib
astrazeneca
['osimertinib', 'tagrisso']
taking the drug osimertinib, which is marketed under the name tagrisso, dramatically reduced the risk of death by 51 percent in patients whose tumours were removed surgically, according to the results presented at an american society of clinical oncology (asco) meeting on sunday.
updating people with latest news